MK 852
Alternative Names: L 367073Latest Information Update: 15 Feb 1995
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis; Unstable angina pectoris
Most Recent Events
- 15 Feb 1995 Discontinued-II for Thrombosis in USA (IV-injection)
- 15 Feb 1995 Discontinued-II for Thrombosis in USA (PO)
- 15 Feb 1995 Discontinued-II for Unstable angina pectoris in USA (IV-injection)